Post-earnings recap
Reported
Wed, Feb 23, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Biocryst Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell by nearly 6% after the earnings report, likely due to the absence of revenue figures and future guidance. Investors may be concerned about the company's direction without clear financial targets.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +68.05% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach due to the lack of revenue guidance. They highlighted their commitment to advancing their pipeline.
Management did not provide specific revenue guidance for the upcoming quarters.
The company emphasized ongoing efforts in research and development.